FGF-23 and the progression of coronary arterial calcification in patients new to dialysis.

Abigail Khan, Julio A. Chirinos, Harold Litt, Wei Yang, Sylvia E. Rosas

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Fibroblast growth factor 23 (FGF-23), a regulator of phosphorus metabolism, is a risk marker in CKD. FGF-23 has been associated with coronary arterial calcification (CAC), but it is not known whether FGF-23 predicts CAC progression in CKD. The aim of this study was to evaluate the association of FGF-23 with CAC progression in advanced CKD. FGF-23 levels and CAC were measured by electrocardiography-triggered multislice computed tomography in 99 individuals initiating dialysis. Patients were enrolled in the study from April 2008 to July 2010. CAC was calculated using Agatston and calcium volume score. Sixty-seven study participants had repeat CAC measures at 1 year. Linear regression was used to assess the association of FGF-23 with CAC. The mean age of study participants was 50 years; 33% were women, and 64% were black. The median FGF-23 level was 1238 relative units (RU)/ml (interquartile range, 515-2218 RU/ml). According to Agatston score, FGF-23 was not associated with baseline CAC (P=0.14) but was significantly associated with CAC progression. There was a 192.3-Agatston unit change in CAC score per 1-SD change in FGF-23 (P=0.008) in models adjusting for known risk factors for CAC and serum phosphate. This association persisted after adjustment for high-sensitivity C-reactive protein, 25-OH vitamin D levels, and the use of phosphorus binders. Results were similar when change in calcium volume score was used. In individuals with advanced CKD, serum FGF-23 is strongly associated with CAC progression. FGF-23 may be a marker of cardiovascular risk in CKD.

Original languageEnglish (US)
Pages (from-to)2017-2022
Number of pages6
JournalClinical journal of the American Society of Nephrology : CJASN
Volume7
Issue number12
StatePublished - Dec 2012
Externally publishedYes

Fingerprint

Dialysis
Phosphorus
fibroblast growth factor 23
Calcium
Multidetector Computed Tomography
Serum
Vitamin D
C-Reactive Protein
Linear Models
Electrocardiography
Phosphates

ASJC Scopus subject areas

  • Medicine(all)

Cite this

FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. / Khan, Abigail; Chirinos, Julio A.; Litt, Harold; Yang, Wei; Rosas, Sylvia E.

In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 7, No. 12, 12.2012, p. 2017-2022.

Research output: Contribution to journalArticle

Khan, Abigail ; Chirinos, Julio A. ; Litt, Harold ; Yang, Wei ; Rosas, Sylvia E. / FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. In: Clinical journal of the American Society of Nephrology : CJASN. 2012 ; Vol. 7, No. 12. pp. 2017-2022.
@article{453fad0f45404089b3b5d290ede0abac,
title = "FGF-23 and the progression of coronary arterial calcification in patients new to dialysis.",
abstract = "Fibroblast growth factor 23 (FGF-23), a regulator of phosphorus metabolism, is a risk marker in CKD. FGF-23 has been associated with coronary arterial calcification (CAC), but it is not known whether FGF-23 predicts CAC progression in CKD. The aim of this study was to evaluate the association of FGF-23 with CAC progression in advanced CKD. FGF-23 levels and CAC were measured by electrocardiography-triggered multislice computed tomography in 99 individuals initiating dialysis. Patients were enrolled in the study from April 2008 to July 2010. CAC was calculated using Agatston and calcium volume score. Sixty-seven study participants had repeat CAC measures at 1 year. Linear regression was used to assess the association of FGF-23 with CAC. The mean age of study participants was 50 years; 33{\%} were women, and 64{\%} were black. The median FGF-23 level was 1238 relative units (RU)/ml (interquartile range, 515-2218 RU/ml). According to Agatston score, FGF-23 was not associated with baseline CAC (P=0.14) but was significantly associated with CAC progression. There was a 192.3-Agatston unit change in CAC score per 1-SD change in FGF-23 (P=0.008) in models adjusting for known risk factors for CAC and serum phosphate. This association persisted after adjustment for high-sensitivity C-reactive protein, 25-OH vitamin D levels, and the use of phosphorus binders. Results were similar when change in calcium volume score was used. In individuals with advanced CKD, serum FGF-23 is strongly associated with CAC progression. FGF-23 may be a marker of cardiovascular risk in CKD.",
author = "Abigail Khan and Chirinos, {Julio A.} and Harold Litt and Wei Yang and Rosas, {Sylvia E.}",
year = "2012",
month = "12",
language = "English (US)",
volume = "7",
pages = "2017--2022",
journal = "Clinical Journal of the American Society of Nephrology",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "12",

}

TY - JOUR

T1 - FGF-23 and the progression of coronary arterial calcification in patients new to dialysis.

AU - Khan, Abigail

AU - Chirinos, Julio A.

AU - Litt, Harold

AU - Yang, Wei

AU - Rosas, Sylvia E.

PY - 2012/12

Y1 - 2012/12

N2 - Fibroblast growth factor 23 (FGF-23), a regulator of phosphorus metabolism, is a risk marker in CKD. FGF-23 has been associated with coronary arterial calcification (CAC), but it is not known whether FGF-23 predicts CAC progression in CKD. The aim of this study was to evaluate the association of FGF-23 with CAC progression in advanced CKD. FGF-23 levels and CAC were measured by electrocardiography-triggered multislice computed tomography in 99 individuals initiating dialysis. Patients were enrolled in the study from April 2008 to July 2010. CAC was calculated using Agatston and calcium volume score. Sixty-seven study participants had repeat CAC measures at 1 year. Linear regression was used to assess the association of FGF-23 with CAC. The mean age of study participants was 50 years; 33% were women, and 64% were black. The median FGF-23 level was 1238 relative units (RU)/ml (interquartile range, 515-2218 RU/ml). According to Agatston score, FGF-23 was not associated with baseline CAC (P=0.14) but was significantly associated with CAC progression. There was a 192.3-Agatston unit change in CAC score per 1-SD change in FGF-23 (P=0.008) in models adjusting for known risk factors for CAC and serum phosphate. This association persisted after adjustment for high-sensitivity C-reactive protein, 25-OH vitamin D levels, and the use of phosphorus binders. Results were similar when change in calcium volume score was used. In individuals with advanced CKD, serum FGF-23 is strongly associated with CAC progression. FGF-23 may be a marker of cardiovascular risk in CKD.

AB - Fibroblast growth factor 23 (FGF-23), a regulator of phosphorus metabolism, is a risk marker in CKD. FGF-23 has been associated with coronary arterial calcification (CAC), but it is not known whether FGF-23 predicts CAC progression in CKD. The aim of this study was to evaluate the association of FGF-23 with CAC progression in advanced CKD. FGF-23 levels and CAC were measured by electrocardiography-triggered multislice computed tomography in 99 individuals initiating dialysis. Patients were enrolled in the study from April 2008 to July 2010. CAC was calculated using Agatston and calcium volume score. Sixty-seven study participants had repeat CAC measures at 1 year. Linear regression was used to assess the association of FGF-23 with CAC. The mean age of study participants was 50 years; 33% were women, and 64% were black. The median FGF-23 level was 1238 relative units (RU)/ml (interquartile range, 515-2218 RU/ml). According to Agatston score, FGF-23 was not associated with baseline CAC (P=0.14) but was significantly associated with CAC progression. There was a 192.3-Agatston unit change in CAC score per 1-SD change in FGF-23 (P=0.008) in models adjusting for known risk factors for CAC and serum phosphate. This association persisted after adjustment for high-sensitivity C-reactive protein, 25-OH vitamin D levels, and the use of phosphorus binders. Results were similar when change in calcium volume score was used. In individuals with advanced CKD, serum FGF-23 is strongly associated with CAC progression. FGF-23 may be a marker of cardiovascular risk in CKD.

UR - http://www.scopus.com/inward/record.url?scp=84877599062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877599062&partnerID=8YFLogxK

M3 - Article

C2 - 22997345

AN - SCOPUS:84877599062

VL - 7

SP - 2017

EP - 2022

JO - Clinical Journal of the American Society of Nephrology

JF - Clinical Journal of the American Society of Nephrology

SN - 1555-9041

IS - 12

ER -